For decades, cancer therapy has pursued one overriding objective: engaging the cancer cell with greater precision.
That effort has transformed modern oncology.
Researchers have developed antibodies, peptides, hormones, ligands, and other biological carriers that recognize malignant cells with remarkable specificity. Entire therapeutic fields - including Radioligand Therapy (RLT), Antibody-Drug Conjugates (ADCs), and numerous targeted therapies - have emerged from this concept.
The pharmaceutical industry has responded accordingly. Over the past several years, acquisition, licensing, and collaboration agreements involving targeted oncology platforms have reached tens of billions of dollars, often before products entered clinical trials.
The message is clear: precision targeting works.
Yet one important question has received surprisingly little attention.
What happens after the therapeutic agent reaches its target?
Most current technologies begin working immediately after administration: Radioisotopes start emitting radiation. Cytotoxic drugs begin exerting their biological effects. Once treatment is delivered, it functions even off-target and physicians have little or no control over this unwanted effect.
Magneto-Cure believes that this paradigm can be fundamentally improved.
Instead of asking only "Can we reach the cancer cell?", the company asks an additional question:
"Can physicians decide exactly when the treatment begins for an optimal outcome?"
That question forms the foundation of the company's proprietary technology, Magnetocytolysis™.
_________________________________________________________________________________________________
Separating Targeting from Activation
Rather than attaching either a radioactive isotope or a toxic drug to an existing targeting ligand, Magneto-Cure attaches biocompatible magnetic nanoparticles, which serve as the activatable therapeutic agent, to which ligands (often drugs) are conjugated to deliver them to target.
Importantly, the biological carrier itself remains unchanged.
Whether the carrier is an antibody, peptide, hormone, or other targeting molecule, continues performing the function for which it was originally developed: locating cancer cells and penetrating malignant tissue.
Once sufficient nanoparticle accumulation has been confirmed through medical imaging, physicians may apply an externally generated alternating magnetic field.
Only then is the therapeutic mechanism activated.
Neither component is intended to be therapeutically active on its own.
The nanoparticles alone are biologically inert.
The magnetic field alone is harmless.
Only their combination—after intracellular targeting has been achieved—produces the desired therapeutic effect.
According to Prof. Avraham Halbreich, Magneto-Cure's Chief Scientist:
"One of oncology's greatest challenges consists of reaching the target cell exclusively and destroying it without damaging surrounding healthy tissue. Our approach separates these two processes. First comes targeting and intracellular penetration; only afterward do we activate the therapeutic mechanism. A minimal treatment is delivered to a very small area while sparing the patient from an overall traumatism, using a physical effect instead of drugs and ionizing radiation."
________________________________________________________________________________________________
Why Timing Matters
This separation between delivery and activation may provide several important advantages.
Unlike radioligands, which begin emitting radiation immediately after administration, Magnetocytolysis enables physicians to wait until imaging confirms optimal biodistribution before treatment is initiated.
Different evacuation rates from non-targeted tissues may also contribute to achieve a favorable biodistribution of nanoparticles to occur before activation potentially reducing exposure of healthy tissues further.
Another distinguishing feature is flexibility.
Depending on the clinical circumstances, activation may be applied to a broad area or focused on highly localized anatomical targets.
Most importantly, treatment can be tailored to each individual patient.
________________________________________________________________________________________________
Rethinking the Therapeutic Payload
Magneto-Cure is not attempting to replace the remarkable targeting biology developed by the pharmaceutical industry.
On the contrary.
The company's long-term vision is to leverage it.
Hundreds of ligands, antibodies, peptides, hormones, and targeted drugs have already undergone years of research and, in many cases, regulatory approval.
Rather than developing entirely new targeting molecules, Magneto-Cure intends to combine proven targeting agents with magnetic nanoparticles, creating what the company calls Magneto-Ligands™.
If successful, this strategy could capitalize on decades of biological innovation instead of rebuilding targeting technology from the ground up. It will also shorten the time to regulatory authorization.
As CEO Ze'ev Harel explains:
"Billions of dollars have already been invested in developing extraordinary targeting mechanisms. We are not trying to replace them. We simply ask whether those same targeting systems can be paired with a safer, externally controlled destruction mechanism."
___________________________________________________________________________________________
Beyond Radioactivity
Another potential advantage arises from the mechanism responsible for cell destruction.
Rather than relying on radioactive decay or chemically toxic payloads carried by each targeting molecule, Magnetocytolysis employs externally controlled physical activation, potentially reducing mutagenic risk.
If validated experimentally, this may become particularly important for younger patients, including younger patients, people of reproductive potential, lactating women where appropriate, sensitive populations, and patients requiring repeated treatments over time.
According to the company's internal analyses, certain clinical applications of magnetocytolysis could require substantially smaller quantities of active material than conventional approaches.
_______________________________________________________________________________________________
A Different Development Strategy
Magneto-Cure is also pursuing an unconventional business model.
Instead of building large internal laboratories, the company collaborates with leading academic institutions, including:
· Hebrew University of Jerusalem (HUJI)
· MD Anderson Cancer Center (MDACC)
· The University of Texas Health Science Center at Houston (UTH)
Its strategy is intentionally time- and capital-efficient.
The company plans to complete proof-of-concept studies, preclinical development, and preparation for first-in-human clinical studies before partnering with major pharmaceutical companies for late-stage clinical development, manufacturing, regulatory approval, and worldwide commercialization.
This partnership-driven model allows resources to be concentrated on scientific innovation and validation rather than infrastructure.
________________________________________________________________________________________________
Looking Beyond Major Cancer Centers
Magneto-Cure also envisions simplifying how advanced oncology treatments could eventually be delivered.
Because magnetic activation systems may require significantly less infrastructure than many existing treatment platforms, future systems could potentially be deployed beyond large tertiary medical centers - including community clinics, rural hospitals, developing countries, and even mobile treatment units.
The company further anticipates incorporating a centralized, AI-assisted image fusion and interpretation platform, enabling MRI data and nanoparticle imaging to guide both the timing and location of treatment activation, and, moreover, ensure homogeneously high-quality treatment even without expert radiologists on site.
The Next Generation of Precision Medicine?
Modern oncology has demonstrated that reaching cancer cells with extraordinary precision is possible.
Magneto-Cure believes the next frontier may be equally important:
not only reaching the right cells – but doing it precisely while avoiding prolonged exposure to toxic drugs, damage to adjacent healthy tissues and side effects.
If that concept ultimately proves successful in clinical development, precision medicine may evolve from targeted drug delivery toward externally controlled, image-guided therapeutic activation - a shift that could redefine how targeted therapies are designed and delivered.
_________________________________________________________________________________________________
Forward-Looking Statement
The concepts, applications, and potential advantages described in this article reflect the company's current research strategy and scientific hypotheses. Magnetocytolysis remains under development, and many proposed indications and anticipated benefits have not yet been demonstrated in human clinical trials. Future clinical, regulatory, and commercial outcomes remain subject to further research and validation.
In collaboration with Ze'ev Harel and Magneto-Cure
